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Introduction
Prostate cancer is a disease of increasing significance worldwide 
and one of the most common cancers and leading causes of death in 
industrialized 1nations [1]. Localized or organ confined disease offers 
the best chance of cure and therefore in patients with this disease, it is 
critical to have an accurate prediction of the final pathological stage, so 
that the appropriate therapy can be given [2]. The treatment options for 
localized prostate cancer include radical prostatectomy, external beam 
radiation therapy or brachytherapy, active surveillance or hormonal 
therapy [3]. Radical prostatectomy (RP) is the treatment which is 
known to be most effective for the localized disease [4,5].  
Several nomograms have been developed to predict the final 
pathological stage as no single clinical test or examination finding can 
accurately predict this. Among these, Partin’s table is most widely used 
in clinics worldwide. This table was developed from a selective group 
of patients with localized prostate cancer in U.S. & can estimate the 
pathological stage from clinical parameters like pre-treatment PSA 
level, clinical stage and biopsy Gleason score [6]. It therefore helps 
urologists, radiation oncologists, medical oncologists and general 
practitioners in predicting the expected disease stage ranging from 
organ confined status to lymph node metastasis, if the prostate is 
removed surgically [7].
Although this model has been both internally and externally 
validated, there are always concerns whether it can be applied to the 
patient population outside U.S. The biological behavior of prostate 
cancer differs between the Asian and Western populations [2]. Also, 
there are differences in screening, selection and treatment protocols.
The predictive value of Partin’s table has not been established for 
Pakistani population therefore, in this study, we evaluated the validity 
of current Partin table updated in 2007 in a subset of surgically treated 
patients with clinically localized prostate cancer. 
Materials and Methods
This was a retrospective analysis of data over a period of 12 years 
from Jan 1998- June 2009. The clinical and pathologic data of patients 
who had bilateral pelvic lymph node dissection with intent to treat by 
radical prostatectomy for localized prostate cancer by a single surgeon 
(FA) at the Aga Khan University and hospital were reviewed. Patients 
with incomplete/ missing data, those whose biopsies were done outside 
our hospital and were not available for review or who had neo-adjuvant 
hormonal or radiation treatment were excluded. The final study 
population consisted of 109 patients. The pre-operative clinical and 
pathological data included serum PSA level (within 6 weeks prior to the 
surgery), the clinical stage as determined by digital rectal examination 
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Abstract
Objectives: To establish the usefulness and validity of 2007 Partin’s table in our population with prostate 
cancer. 
Materials and methods: Between January 1998 to June 2009, all patients with clinically localized carcinoma 
prostate who were treated with intent of radical retro-pubic prostatectomy (RRP) were included. Clinical, operative 
and pathological data was gathered. All biopsy and final histopathology Gleason scores were re-assigned in a 
double blind manner. Pre-operative serum PSA, TNM clinical stage and biopsy Gleason scores were plotted on 
Partin’s table and its predictive value and pathological findings of specimen were compared and analyzed by using 
Receiver operating characteristic (ROC) analysis.
Results: A total of 109 of 138 patients were included in final analysis. The median age was 65 ± 5.8 years. The 
pre-operative serum PSA values and clinical stages were higher in our cohort of patients as compared to Partin’s 
cohort. At pathological assessment of resected specimen, organ confined disease was present in 58 % of patients, 
seminal vesicles were involved in 22 % and lymph node metastasis was present in 12 % of patients. The accuracy 
of Partin’s table derived probability was high with area under curve (AUC) of 0.82 for organ confinement, 0.805 for 
seminal vesicle involvement and 0.714 for lymph node involvement respectively.
Conclusions: The 2007 Partin’s table has a reasonably high predictive value for the final histo-pathological 
features. This predictive model can be used in Pakistani patients with carcinoma prostate with comparable accuracy. 
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and was assigned according to 2002 AJCC staging system and biopsy 
Gleason score. All patients had ultrasound guided systemic sextant (six 
cores) or octant (eight core) biopsy done. Both the biopsy slides and 
prostatectomy specimen slides were reviewed by a single dedicated 
histo-pathologist (ZA) in a double blinded manner and these were 
graded histologically using Gleason scoring system according to the 
2005 ISUP consensus. 
The final pathological stage was categorized in each patient as 
outlined in Partin’s table. This included gradual progression of disease 
as follows; organ confined disease (OC) as long as prostatic capsule 
was not breached by tumor, extra-prostatic extension (EPE) if tumor 
reached the inked surface i.e. surgical margin was positive, Seminal 
vesicle invasion (SVI) if patient had invasion of seminal vesicles 
without lymph node involvement and lymph node involvement (LNI) 
if patient has lymph node involvement.
All statistical analyses were performed on a commercially available 
SPSS software package. The 2007 updated Partin’s table was applied to 
our patients and based on the pre-operative parameters (PSA, Clinical 
stage, and Gleason grade) the prediction of organ confinement, seminal 
vesicle and lymph node involvement was calculated. Sensitivity and 
specificity of Partin tables was calculated and Receiver operating 
characteristics (ROC) analysis was done to assess the discriminative 
ability of this table in our patient population.
Results
A total of 138 patients were operated with the intent of radical 
retropubic prostatectomy (RRP) during the study period, of which 109 
(79 %) fulfilling the criteria were included in final analysis. 90 patients 
(83%) had RRP with bilateral negative pelvic lymph node dissection 
(PLND). In 7 patients with gross lymph node metastases on frozen 
section examination, only bilateral orchidectomy was done while in 12 
patients with microscopic metastases, RRP with bilateral orchidectomy 
was carried out. The median age at presentation was 65 ± 5.83 (49-76) 
years. The clinical and pathological features i.e. pre operative serum 
PSA, biopsy Gleason scores and preoperative clinical stages were 
compared with 2007 Partin’s cohort and are shown in Table 1.
The median pre-operative PSA value was 10.5+/- 6.3 ng/ml (1.5-
58.5) (Abbot Hybritech Assay) and it was higher in our cohort of 
patients as compare to Partin’s cohort. Only 5 % of patients in our 
cohort had serum PSA values less than 4 ng/ml as compare to 25 % 
of patients in Partin’s cohort. A very high proportion (> 50 %) in our 
population had PSA values > 10 ng/ml while Partin’s cohort had only 
12 % of patients in this range of PSA. 44% of patients in our study 
group and 64 % in Partin’s cohort had serum PSA value in gray scale 
i.e. b/w 4.0-10.0 ng/ml. 
The distribution of clinical stage showed a remarkable difference. 
In Partin’s cohort, 77 % of patients had T1c disease and only 6 % had 
T2b/T2c disease. Our cohort showed 30 % and 47 % respectively. The 
median Gleason score was 6 +/- 2.4 (2-10). Patients in our cohort had 
higher Gleason score with 11 % having least favorable disease (Gleason 
8 or >) as compared to only 3 % in Partin’s group. Partin’s cohort had 
77 % of patients with low grade disease (Gleason 6 or <) as compare to 
58 % of our patients.
Final histo-pathological assessment showed that 58 % of patients 
had organ confined disease as compared to 73 % in Partin’s cohort. 
A much higher proportion of our patients had seminal vesicle 
involvement and lymph node metastases i.e. 22 % and  12 %, while only 
3 % and 1 % had that in Partin’s cohort, respectively.
A comparison of biopsy Gleason and final histopathology Gleason 
showed up grading in 21 % of patients while 64 % had similar grade 
(Table 2).
The accuracy and discriminative ability of Partin tables were 
assessed using ROC analyses. The AUC for organ confined disease was 
0.82 (95 % CI 0.742-0.897), for seminal vesicle involvement 0.80 (95 % 
CI 0.717 -0.893) and that for lymph node involvement was 0.714 (CI 
0.6-0.83) (Figures 1-3).
Discussion
Prostate cancer is the 2nd most common cancer in men and fifth 
most common cancer in the world [1]. Early detection and appropriate 
treatment can reduce prostate cancer related morbidity and mortality. 
Many nomograms have been developed for providing diagnostic, 
staging and prognostic information in patients with prostate cancer 
[9]. Oesterling et al. [10] in 1987 reported a model including the 
combination of pre operative variables like clinical stage, serum acid 
phosphatase and pre operative Gleason score to predict the final 
pathological stage in patients with clinically localized prostate cancer as 
compare to individual variables alone. The pathological stage of disease 
Pakistan 2009
(n=109 ) 
 Partin 2007*
(n= 5730 ) 
CLINICAL STAGE 
T1c 33 (30) 4419 (77) 
T2a 25 (23) 998(17) 
T2b/T2c 51 (47) 313 (6) 
PSA (ng/ml) Δ
0-2.5 3 (3) 452 (8) 
2.6-4.0 2 (2) 946 (17) 
4.1-6.0 15 (14) 1994 (35) 
6.1-10.0 34 (31) 1671 (29) 
>10.0 55 ( 50) 667 (12) 
BIOPSY GLEASON SUM 
5-6 63 (58) 4402 (77) 
3+4=7 23 (21) 816 (14) 
4+3=7 11 (10) 348 (6) 
8-10 12 ( 11) 164 (3) 
PATHOLOGICAL STAGE 
Organ confined 63 (58) 4204 (73) 
Extra prostatic extension 9 (8) 1276 (22) 
Seminal vesicle involvement 24 (22) 180 (3) 
Lymph node metastasis 13 (12) 70 (1) 
* Makarov et al. [13].
ΔAbbot Hybritech Assay
Table 1: Comparison of Clinical and pathological features.
Gleason final Histo-pathology N (%)**
Same 65 (63.7) 
Up grade 22 (21.6) 
Down grade 15 (14.7) 
** Patients with PLND & orchidectomy were excluded [7].
Table 2: Comparisons of Biopsy Gleason score and final histopathology Gleason 
scores.
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determines the final choice of treatment. Partin tables were designed 
to provide the pathological stage predictions and to guide treatment 
decisions. 
The validation studies of former Partin tables (1997 and 2001) have 
confirmed its accuracy not only for United States but also for Europe 
and Asian cohorts [2,11,12] and showed that these tables can be applied 
to other population cohorts as well. The Partin’s table was updated 
in 2007 by Makarove et al. [13] and its accuracy and discriminative 
properties have been questioned in various external validation studies 
[7,14,15]. These studies have shown poor relationship between 
predicted probabilities and observed rates and demonstrated worse 
performance in populations other than U.S.
Naito et al. [2] suggested that as it takes into account the ethnic 
differences, variation in prostate gland sizes and biological behavior of 
the disease, a nomogram based on population of interest is expected 
to predict the pathological stage better than one developed in an 
outside population. Ethenic differences account for marked variation 
in prostate cancer incidence and mortality rates with very high rates 
amongst African Americans and lowest rates amongst men from South 
East Asia and China [16,17]. 
Our study cohorts and Partin’s cohort are quite different in terms 
of the extent and nature of disease. Only 30 % of our study patients 
compared with 77% in Partin’s series had clinical stage T1c disease 
[13]. This is due to delayed diagnosis and lack of implementation of 
early detection methodologies for prostate cancer in our population. 
More than half of our patients had serum PSA levels >10 ng/ml 
compared to only 12 % in Partin’s cohort. Despite higher clinical stage 
and PSA levels at diagnosis, 58 % of our patients had pathologically 
organ confined disease as compare to 73 % in Partin’s cohort. 22 % of 
our patients had seminal vesicle involvement and 12 % had lymph node 
metastases. In the recent Partin’s table [13], the prevalence of seminal 
vesicle and lymph node involvement was 3 % and 1 % respectively. 
Pelvic lymph node dissection (PLND) is the most accurate and 
reliable staging procedure for the detection of lymph node invasion 
in prostate cancer [18]. There is still a debate about the extent of 
dissection i.e. limited vs. extended and in which patients it should be 
done [19]. There is no prospective randomized clinical trial which has 
tested the impact of PLND on prostate cancer outcome. Limited PLND 
may be associated with high rate of false negative findings and it is now 
recommended to have more extended PLND in order to have a more 
accurate assessment of lymph nodes and nodal metastases. Briganti et 
al. [20] and Studer and Collette [21] have reported a high prevalence 
of lymph node metastasis exceeding 10 % when extended PLND is 
performed and therefore the updated Partin tables will be limited in 
predicting lymph node involvement in cohort of patients who undergo 
extensive PLND. For our patients, we performed limited pelvic lymph 
node dissection for staging purposes only. 
Area under curve (AUC) values has been assessed previously for 
evaluating the predictability of Partin tables in external validation 
studies [11,12,14,15]. The ideal predictions are donated with 100 % 
accuracy and values of 50 % or less indicates that the model cannot 
predict the desired outcome but rather describes the only random 
Figure 1: ROC analysis for predicted probabilities of organ confinement.
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Figure 2: ROC analysis for predicted probabilities of seminal vesicle 
involvement.
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Figure 3: ROC analysis for predicted probabilities of lymph node 
involvement.
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predictions. Therefore, values of less than 70% may be considered as 
a poor result.
Despite the apparent differences in pre-operative variables of 
our cohort and the derivation cohort of updated Partin’s table, the 
predicted accuracy for the final pathological status was good. Our AUC 
values for organ confined disease (OC), Seminal vesicle involvement 
(SVI) and Lymph node involvement (LNI) predictions were 82 %, 80.5 
% and 71.4 % respectively which show that the relationship between 
the predicted probabilities and observed results are good. This suggests 
that Partin’s table would incorrectly classify only 18 %, 19.5 % and 
28.6% of patients with respect to OC, SVI and LNI. 
Histological grading of prostate biopsy specimens is one of the 
main determinants of prostate cancer treatment [6] and pathological 
Gleason score of RP specimen is a better predictor of biochemical 
recurrence than biopsy score [22,23]. Our study showed Gleason 
upgrading from biopsy to final pathology of 21.6 %. This is similar to 
the several retrospective studies which have demonstrated inadequate 
concordance rates between  biopsy and pathological Gleason sum [22-
24] . Previous studies indicated that as many as 43 % of men with low 
grade prostate cancer on biopsy will be finally diagnosed with high 
grade disease on radical prostatectomy [6,22-24]. Low Gleason score 
on pre treatment biopsy can lead to under treatment for clinically 
significant prostate cancer and likewise a high Gleason on biopsy can 
lead to over treatment. The Gleason down grading of RP specimen was 
14.7 % in our study.
Partin tables provide information only about the final pathological 
outcome and cannot predict the clinical outcome and therefore are 
not the ideal tools for further treatment planning. However, they can 
guide towards the type and extent of prostatectomy like nerve sparing 
to preserve the neuro-vascular bundle in patients with organ confined 
disease and need for routine lyphadenectomy or not.
Due to limitation of Partin tables, for the better counseling in 
the individual patients artificial neural networks (ANN) offer a more 
tailored treatment decision [25]. These ANN models were developed 
with reference to decision making process of the human brain and 
can improve the ability to predict organ confined and lymph node 
involvement more accurately in an individual  than population based 
nomograms [26].
Our study has several limitations. It has a small sample size and 
was carried out in a tertiary care university teaching hospital setting 
rather than in a community based setting. The other validation 
studies included populations from various centers whilst ours in 
only a single centre study. The small sample size can over reflect the 
higher proportion of lymph node involvement and seminal vesicle 
involvement in our patient group. All the biopsy slides and pathology 
specimen were re-reviewed by a single histo-pathologist in a double 
blind manner which might decrease the inter observer variability in 
grading the tumor, however it does not reflect the real world practice. 
To our knowledge, this is the first ever study which has determined 
the accuracy and discriminative properties of Partin tables from the 
South East Asian population, and therefore it can be used as a clinical 
decision making tool for patients with prostate cancer.
Conclusions
The 2007 Partin’s table has a reasonable predictive value for the 
final histo-pathological features like organ confinement, seminal vesicle 
and lymph node involvement in our limited series. This predictive 
model can be used in Pakistani patients with carcinoma prostate with 
comparable accuracy.  
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